Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Gray SL, Williams DM, Pulliam CC, Sirgo MA, Bishop AL, Donohue JF
For real-time expiration data, Paragraph IV filing tracking, and competitive intelligence on specific assets, consult DrugPatentWatch.
Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/-catenin signaling
Transforming boundaries, breaking barriers, setting new standards, disrupting the status quo
Novartis is investing in expanding Pluvicto's label into pre-taxane prostate cancer (SPLASH trial submission pending), and developing next-generation RLT approaches targeting breast cancer and other tumour types positioning it to maintain leadership in the highest-growth oncology peptide segment
US$ 21.58
US$ 28.98
US$ 21.99
US$ 29.13
